Tvardi TherapeuticsLTS:0HTC 12 EBIT per Share is £-2.41 as of Mar. 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,173 Biotechnology companies, Tvardi Therapeutics ranks better than 62.49% on this metric.
Tvardi Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was £-0.56.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was £-2.41.
During the past 3 years, the average EBIT per Share Growth Rate was 25.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Tvardi Therapeutics's EBIT per Share or its related term are showing as below:
LTS:0HTC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 25.3 Med: 25.3 Max: 25.3
Current: 25.3
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Tvardi Therapeutics was 25.30% per year. The lowest was 25.30% per year. And the median was 25.30% per year.
LTS:0HTC's 3-Year EBIT Growth Rate is ranked better than 62.49% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs LTS:0HTC: 25.30
Tvardi Therapeutics (LTS:0HTC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Tvardi Therapeutics EBIT per Share Related Terms
Tvardi Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Tvardi Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was £-2.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tvardi Therapeutics (LTS:0HTC) has a EBIT per Share of £-2.41 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tvardi Therapeutics and its competitors. According to the industry distribution chart, Tvardi Therapeutics ranks #440 out of 1173 companies in the Biotechnology industry, placing it in the top 37.5%.
Is Tvardi Therapeutics' EBIT per Share too high?
Tvardi Therapeutics' current EBIT per Share is £-2.41. Based on the distribution chart, Tvardi Therapeutics ranks #440 out of 1173 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' EBIT per Share compare to HOWL and TPST?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #440 out of 1173 companies for EBIT per Share. This puts Tvardi Therapeutics in the upper half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tvardi Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tvardi Therapeutics's current EBIT per Share is £-2.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current EBIT per Share of £-2.41. The current EBIT per Share is £-2.41. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current EBIT per Share is £-2.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTC has been successfully added to your 